S&P advises and acts for Carlyle and Viyash Life Sciences in multiple acquisitions

LE Desk

New Delhi, November 23, 2021: Saraf and Partners (S&P) has advised and acted for Carlyle and Viyash Life Sciences in multiple acquisitions as part of its pharmaceutical platform in India, the Law Firm said.

In a press statement, the Law Firm said it acted for and advised CA Hull Investments — an affiliated entity of global investment firm The Carlyle Group — and Viyash Life Sciences Private Limited — a leading manufacturer of Active pharmaceutical ingredients (API) intermediates in India — in undertaking certain acquisitions in pharmaceutical sector in India and US as part of its integrated generic pharmaceutical platform in India.

Specifically, Viyash acquired controlling stake in Symed Labs Limited – a leading manufacturer of APIs in India through secondary purchase from certain existing shareholders of Symed Labs, at an undisclosed valuation.

The team at S&P that acted for and advised Carlyle and Viyash on all aspects of the Symed Transaction, with the core transaction team for the Symed Transaction, comprised of Partners – Vaibhav Kakkar, Sahil Arora and Snigdhaneel Satpathy; Senior Associate – Debarpan Ghosh and Associates – Keshav Pareek and Paayas Pandit. Partners Sachit Mathur and Astha Singh Trehan also provided assistance in relation to the Real Estate related aspects involved in the deal, the statement said.

Viyash also acquired controlling stake in Appco Pharma LLC – a formulations player focused on the US market for an undisclosed amount. The team at S&P that acted for and advised Carlyle and Viyash Life Sciences on Appco Pharma Transaction from an Indian regulatory standpoint with the core transaction team comprising of Partners – Vaibhav Kakkar and Sahil Arora; and Senior Associate – Debarpan Ghosh.

Ropes and Gray advised Carlyle and Viyash Life Sciences from a US law standpoint.